- |||||||||| zoledronic acid / Generic mfg., alendronate / Generic mfg.
Journal: Paget's bone disease in a nonendemic region: Exploring novel therapeutic strategies. (Pubmed Central) - Sep 1, 2024 We recommended Fosamax (70?mg alendronate tablets) at two tablets twice weekly for 3?months to manage PDB due to patient preference and side effects with intravenous zoledronic acid. Subsequent assessments of alkaline phosphatase levels during follow-up examinations post-treatment revealed a reduction in their values.
- |||||||||| Xofigo (radium Ra-223 dichloride) / Bayer
Review, Journal: Role of osteoclast inhibitors in prostate cancer bone metastasis; a narrative review. (Pubmed Central) - Aug 22, 2024 Long-term studies are needed to investigate potential effects on mortality during extended treatment periods. Osteoclast inhibitors are effective in reducing skeletal related events in advanced bone metastasis and improve the quality of life of patients.
- |||||||||| alendronate / Generic mfg.
Journal: Declining Trend in Anti-osteoporotic Treatment, Despite a Rise in DEXA Screening Following "Sentinel" Distal Radius Fractures. (Pubmed Central) - Aug 21, 2024 Factors associated with increased odds of receiving anti-osteoporotic medication were age 70 to 79 years (odds ratio [OR], 1.45; P = .014), age 80 to 89 years (OR, 1.66; P = .001), Asian (OR, 2.95; P = .002) or Hispanic (OR, 1.77; P = .006) ethnicity, belonging to South (OR, 1.19; P = .029) or West (OR, 1.37; P = .010), and having an Elixhauser Comorbidity Index score of 3 (OR, 2.14; P = .024) or > 3 (OR, 2.05; P = .022). Despite a rising utilization of DEXA screening following "sentinel" distal radius fractures, the proportion of individuals who receive anti-osteoporotic treatment is decreasing over time.
- |||||||||| alendronate / Generic mfg.
Journal: Intelligent Supramolecular Modification for Implants: Endogenous Regulation of Bone Defect Repair in Osteoporosis. (Pubmed Central) - Aug 21, 2024 Furthermore, osteoblasts secrete alkaline phosphatase (ALP), which significantly hydrolyzes phosphate ester bonds in surface macromolecular side groups, resulting in the release of alendronate (ALN)...This intelligent surface modification tailors bone repair to individual conditions, automatically realize multiple endogenous regulation once implanted, and truly realize spontaneous activation of a series of responses conducive to bone repair in vivo. It is evidenced by improved bone regeneration in iron-overloaded osteoporotic rabbits and supported by in vitro validations.
- |||||||||| alendronate / Generic mfg.
Journal: Alendronate Functionalized Bone-Targeting Pomolic Acid Liposomes Restore Bone Homeostasis for Osteoporosis Treatment. (Pubmed Central) - Aug 13, 2024 In this study, a novel therapeutic agent was designed and constructed to treat osteoporosis, consisting of a liposome material as the drug pocket, PA as the anti-osteoporosis drug, and ALN as the bone-targeting molecule. And our study is the first to employ a bone-targeted delivery system to deliver PA for OVX-induced bone loss, providing an innovative solution for treating osteoporosis.
- |||||||||| alendronate / Generic mfg.
Journal: Autocatalytic bifunctional supramolecular hydrogels for osteoporotic bone repair. (Pubmed Central) - Jul 29, 2024 Herein, multifunctional self-assembled supramolecular fiber hydrogels (Ce-Aln gel) consisting of alendronate (Aln) and cerium (Ce) ions were constructed for osteoporotic bone defect repair...In vivo experiments showed that the clinical drug-based Ce-Aln gel effectively promoted the tissue repair of osteoporotic bone defects by improving inflammation and inhibiting osteoclast formation at the defect. Notably, in vivo systemic osteoporosis was significantly ameliorated, highlighting the strong potential of clinical translation for precise therapy of bone defects.
- |||||||||| Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Clinical, Retrospective data, Review, Journal: Efficacy and Safety of Anti-Osteoporotic Agents Across CKD Stages: A Meta-Analysis of Randomized Clinical Trials. (Pubmed Central) - Jul 26, 2024 However, this benefit is not apparent in stages 4 and 5, necessitating further research. Despite the absence of reported side effects in CKD patients, clinicians should carefully assess the suitability of these medications, considering individual risks and benefits.
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial completion, Trial completion date: Romosozumab in Women With Chronic SCI (clinicaltrials.gov) - Jul 14, 2024 P2, N=12, Completed, In this comparative study of older patients seen in routine practices, denosumab was associated with a lower risk of developing T2DM than alendronate. Active, not recruiting --> Completed | Trial completion date: Feb 2025 --> Jun 2024
- |||||||||| alendronate / Generic mfg.
Journal: Association of bisphosphonate with bone loss and pain-related behavior in an adjuvant-induced osteoporosis model. (Pubmed Central) - Jul 6, 2024 SAPHO syndrome can be managed with drug therapies, such as nonsteroidal anti-inflammatory drugs, methotrexate, and conventional synthetic disease-modifying antirheumatic drugs; however, there are occasional treatment-resistant cases. Alendronate may contribute to pain improvement through the simultaneous effects of bone mass improvement and suppression of osteoporotic pain.
- |||||||||| raloxifene hydrochloride / Generic mfg., alendronate / Generic mfg.
Review, Journal: Antiosteoporosis therapy after discontinuation of menopausal hormone therapy: a systematic review. (Pubmed Central) - Jul 2, 2024 Antiresorptive therapy with either a bisphosphonate (i.e., alendronate) or raloxifene could be considered a sequential antiosteoporosis therapy after MHT withdrawal since they have been shown in studies to further increase BMD. However, no safe conclusions can be drawn from the existing literature.
- |||||||||| alendronate / Generic mfg.
Journal: Alendronate as Bioactive Coating on Titanium Surfaces: An Investigation of CaP-Alendronate Interactions. (Pubmed Central) - Jun 19, 2024 This integrated experimental-theoretical study highlights the spontaneous formation of CaP on the alendronate-coated titanium surface, confirming the bioactivity ability of the alendronate coating. The results provide valuable guidance for the promising forthcoming advancements in the development of biomaterials and surface modification of dental implants.
- |||||||||| alendronate / Generic mfg.
Observational data, Journal: Osteoporosis treatment prevents hip fracture similarly in both sexes: the FOCUS observational study. (Pubmed Central) - Jun 11, 2024 At two-year follow-up, 33.9% of the women (750/2211 patients) and 24.0% of the men (175/728 patients) were treated, primarily with alendronate; 51.3% and 66.3%, respectively, were not-treated; and 721 and 269, respectively, had a first hip fracture since the CT scan...Various sensitivity and stratified analyses confirmed these trends, including results at five-year follow-up. Given these results and considering the relevant literature, we conclude that osteoporosis treatment prevents hip fracture similarly in both sexes.
- |||||||||| alendronate / Generic mfg.
Journal: Fluffy hybrid nanoadjuvants for reversing the imbalance of osteoclastic and osteogenic niches in osteoporosis. (Pubmed Central) - Jun 7, 2024 Despite the development of nationally recognized first-line anti-osteoporosis drugs, including alendronate (AL), their low bioavailability, poor uptake rate, and dose-related side effects present significant challenges in treatment...Therefore, this study constructed a drug nanoadjuvant with peculiar topological structures and high bone targeting capacities, efficient intracellular drug delivery as well as bone bioactivity. This provides a novel perspective on drug delivery for osteoporosis and treatment strategies for other bone diseases.
|